Activated thrombin‐activatable fibrinolysis inhibitor (TAFIa) attenuates fibrin‐dependent plasmin generation on thrombin‐activated platelets
Ran Ni(Thrombosis and Atherosclerosis Research Institute), Paul Y. Kim(McMaster University Medical Centre), Heyu Ni(St. Michael's Hospital), Peter L. Gross(Thrombosis and Atherosclerosis Research Institute), Miguel A. D. Neves(Universidade do Porto), Jeffrey I. Weitz(McMaster University Medical Centre), Samantha E. Cerroni(Thrombosis and Atherosclerosis Research Institute), Chengliang Wu(Thrombosis and Atherosclerosis Research Institute), Matthew J. Flick(University of North Carolina at Chapel Hill)
Cited by 23
Related Papers
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
|Journal of the American College of Cardiology|2020|2.9k
Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.
|Journal of Clinical Investigation|1990|1.1k
Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis
|New England Journal of Medicine|2014|621
Leukocyte engagement of fibrin(ogen) via the integrin receptor αMβ2/Mac-1 is critical for host inflammatory response in vivo
|Journal of Clinical Investigation|2004|438
Venous thrombosis
|Nature Reviews Disease Primers|2015|378